title: Sequential DICE combined with l-asparaginase chemotherapy followed by involved field radiation in newly diagnosed, stage IE to IIE, nasal and extranodal NK/T-cell lymphoma.
abstract: Extranodal natural killer (NK)/T-cell lymphoma is an aggressive lymphoid tumor. Optimal treatment strategies have not yet been fully defined. To explore a more effective treatment, we conducted sequential chemoradiotherapy (SCRT) and evaluated the safety and efficacy. Seventy-eight patients (51 males, 27 females) were analyzed. The complete response (CR) rate was higher for patients in the SCRT group (90.9%) than in the radiotherapy group (77.8%; p = 0.124). The relapse rate (RR) and death rate (DR) were lower in the SCRT group (RR: 6.7% vs 33.3%, p < 0.001; DR: 15.2% vs. 55.6%, p < 0.001). Progression-free survival (PFS) and overall survival (OS) rates of 5 years after diagnosis were significantly higher for patients in the SCRT group (PFS: 89%; OS: 82%) than in the radiotherapy group (PFS: 49%, p < 0.001; OS: 49%, p < 0.001). Treatment-related adverse events were more common in the SCRT group. However, the adverse events were controlled.
authors.affiliation: a Department of Hematology , Henan Provinal Institute of Hematology, The Affiliated Cancer Hospital of Zhengzhou University , Zhengzhou , Henan Province , P.R. China ;
authors.forename: Li-Hua
authors.initials: LH
authors.lastname: Dong
authors.affiliation: a Department of Hematology , Henan Provinal Institute of Hematology, The Affiliated Cancer Hospital of Zhengzhou University , Zhengzhou , Henan Province , P.R. China ;|b Transplantation Department of Internal Medicine , 302 Hospital of the Chinese People's Liberation Army , Beijing , P. R. China.
authors.forename: Li-Juan
authors.initials: LJ
authors.lastname: Zhang
authors.affiliation: a Department of Hematology , Henan Provinal Institute of Hematology, The Affiliated Cancer Hospital of Zhengzhou University , Zhengzhou , Henan Province , P.R. China ;
authors.forename: Wen-Jia
authors.initials: WJ
authors.lastname: Wang
authors.affiliation: a Department of Hematology , Henan Provinal Institute of Hematology, The Affiliated Cancer Hospital of Zhengzhou University , Zhengzhou , Henan Province , P.R. China ;
authors.forename: Wen
authors.initials: W
authors.lastname: Lei
authors.affiliation: a Department of Hematology , Henan Provinal Institute of Hematology, The Affiliated Cancer Hospital of Zhengzhou University , Zhengzhou , Henan Province , P.R. China ;
authors.forename: Xing
authors.initials: X
authors.lastname: Sun
authors.affiliation: a Department of Hematology , Henan Provinal Institute of Hematology, The Affiliated Cancer Hospital of Zhengzhou University , Zhengzhou , Henan Province , P.R. China ;
authors.forename: Jian-Wei
authors.initials: JW
authors.lastname: Du
authors.affiliation: a Department of Hematology , Henan Provinal Institute of Hematology, The Affiliated Cancer Hospital of Zhengzhou University , Zhengzhou , Henan Province , P.R. China ;
authors.forename: Xue
authors.initials: X
authors.lastname: Gao
authors.affiliation: a Department of Hematology , Henan Provinal Institute of Hematology, The Affiliated Cancer Hospital of Zhengzhou University , Zhengzhou , Henan Province , P.R. China ;
authors.forename: Gang-Ping
authors.initials: GP
authors.lastname: Li
authors.affiliation: a Department of Hematology , Henan Provinal Institute of Hematology, The Affiliated Cancer Hospital of Zhengzhou University , Zhengzhou , Henan Province , P.R. China ;
authors.forename: Yu-Fu
authors.initials: YF
authors.lastname: Li
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001215:Asparaginase / Q000008:administration & dosage; D059248:Chemoradiotherapy; D002648:Child; D002945:Cisplatin / Q000627:therapeutic use; D003131:Combined Modality Therapy; D003907:Dexamethasone / Q000627:therapeutic use; D005047:Etoposide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007069:Ifosfamide / Q000627:therapeutic use; D054391:Lymphoma, Extranodal NK-T-Cell / Q000175:diagnosis* / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D005047:Etoposide; D003907:Dexamethasone; D001215:Asparaginase; D002945:Cisplatin; D007069:Ifosfamide
keywords: DICE regimen; l-asparaginase; nasal natural killer/T-cell lymphoma treatment